National Vaccine
Information Center

Your Health. Your Family. Your Choice.

MedAlerts Home
Search Results

From the 11/26/2021 release of VAERS data:

This is VAERS ID 1412506

Government Disclaimer on use of this data

Case Details

VAERS ID: 1412506 (history)  
Form: Version 2.0  
Sex: Male  
Location: Unknown  
Submitted: 0000-00-00
Entered: 2021-06-19
Vaccin­ation / Manu­facturer Lot / Dose Site / Route

Administered by: Unknown       Purchased by: ?
Symptoms: Activated partial thromboplastin time prolonged, Alanine aminotransferase, Antibody test negative, Antibody test positive, Aspartate aminotransferase, Blood albumin, Body mass index, Brain natriuretic peptide increased, C-reactive protein, C-reactive protein increased, Cytomegalovirus test negative, Echocardiogram, Electrocardiogram, Enterovirus test negative, Epstein-Barr virus antibody negative, International normalised ratio, Laboratory test, Lymphocyte count, Magnetic resonance imaging, Myocarditis, Neutrophil count, Platelet count, Polymerase chain reaction, Prothrombin time, Red blood cell sedimentation rate, SARS-CoV-2 antibody test positive, SARS-CoV-2 test negative, Serum ferritin, Troponin T, Troponin T increased, White blood cell count
SMQs:, Cardiac failure (broad), Haemorrhage laboratory terms (broad), Myocardial infarction (narrow), Pulmonary hypertension (broad), Cardiomyopathy (broad), Vasculitis (broad), Hypersensitivity (broad), Drug reaction with eosinophilia and systemic symptoms syndrome (broad), Infective pneumonia (broad), Opportunistic infections (broad), Immune-mediated/autoimmune disorders (broad), COVID-19 (narrow)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? Yes, 3 days
   Extended hospital stay? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions:
Diagnostic Lab Data: Test Name: Partial thromboplastin time; Test Result: 27.9 s; Test Name: Alanine transaminase; Result Unstructured Data: Test Result:22 IU/l; Comments: (units/L); Test Name: COVID-19 nucleocapsid antibody; Test Result: Negative ; Test Name: Antibody test; Test Result: Positive ; Comments: antibody testing showed positive spike and negative nucleocapsid antibodies for SARS-CoV-2; Test Name: Aspartate transaminase; Result Unstructured Data: Test Result:59; Comments: (units/L); Test Name: Albumin; Result Unstructured Data: Test Result:3.8 g/dl; Test Name: BMI; Result Unstructured Data: Test Result:22; Test Name: NT pro-BNP; Result Unstructured Data: Test Result:149 pg/mL; Test Name: C-reactive protein; Test Result: 1.5 mg/dl; Test Name: Highest C-reactive protein; Test Result: 1.8 mg/dl; Test Name: Cytomegalovirus Disagnostics; Test Result: Negative ; Test Name: Echocardiogram; Result Unstructured Data: Test Result:Normal; Test Name: ECG; Result Unstructured Data: Test Result:ST-Elevated; Comments: ST-elevation on ECG but normal function; Test Name: Enterovirus diagnostics; Test Result: Negative ; Test Name: Epstein-Barr virus Diagnostics; Test Result: Negative ; Test Name: International Normalized Ratio INR; Result Unstructured Data: Test Result:1.06; Test Name: lab test; Result Unstructured Data: Test Result:Negative Lyme; Comments: Other diagnostics: Negative Lyme serology, negative Mycoplasma serum PCR, negative Parvovirus serum PCR; Test Name: Absolute lymphocyte count; Result Unstructured Data: Test Result:1.4 /mm3; Test Name: MRI; Result Unstructured Data: Test Result:demonstrated diffuse edema; Comments: Cardiac MRI demonstrated diffuse edema; Test Name: Absolute neutrophil; Result Unstructured Data: Test Result:2.8 /mm3; Test Name: Platelet count; Result Unstructured Data: Test Result:189 /mm3; Test Name: Mycoplasma serum PCR; Test Result: Negative ; Test Name: Respiratory pathogen panel PCR; Test Result: Negative ; Test Name: Prothrombin time; Test Result: 11.4 s; Test Name: Erythrocyte sedimentation rate; Result Unstructured Data: Test Result:3; Comments: (mm/hr); Test Name: COVID-19 spike antibody; Test Result: Positive ; Test Name: Nasopharyngeal SARS-CoV-2 PCR; Test Result: Negative ; Test Name: Ferritin; Result Unstructured Data: Test Result:65 ug/L; Test Name: Highest troponin; Result Unstructured Data: Test Result:0.82 ng/ml; Test Name: Lowest troponin prior to Discharge; Result Unstructured Data: Test Result:0.01 ng/ml; Test Name: Elevated troponin T; Result Unstructured Data: Test Result:0.66 ng/ml; Comments: Evaluation in the ED showed an elevated troponin T (0.66 ng/mL, normal range, <0.01 ng/mL); Test Name: Peripheral white blood cell count; Result Unstructured Data: Test Result:5.0 /mm3
CDC Split Type: USPFIZER INC2021665019

Write-up: This is a literature report from the Pediatrics, 2021, entitled Symptomatic Acute Myocarditis in Seven Adolescents Following Pfizer BioNTech COVID-19 Vaccination with DOI: 10.1542/peds.2021-052478. Additionally reported in Pediatrics, 2021, entitled Myocarditis after SARS-CoV-2 Vaccination: True, True, and Related? with DOI: 10.1542/peds.2021-052644 via contactable Physicians. This Physician reported similar events for seven patients. This is the sixth of seven reports. Introduction: On 11Dec2020, the FDA issued an Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 mRNA vaccine for prevention of COVID-19 for individuals 16 years of age and older.1. On 10May2021, the FDA revised the EUA for this vaccine to include children 12 years and older. The Pfizer vaccine remains the only vaccine with an EUA for 12-to 17-year-old children. This vaccine demonstrated 94-95% efficacy in preventing COVID-19 infection in 16- 55-year-old participants, and 100% efficacy in the 12-15 years old age group. Systemic reactogenicity occurred more commonly in younger patients and after the second dose of vaccine. Post-immunization myocarditis is a known rare adverse event following other vaccinations, particularly following smallpox vaccination. Recently the news media has highlighted reports of myocarditis after COVID-19 mRNA vaccination involving United States (US) military patients and patients from Israel. The Israeli cohort identified a male predominance with an incidence of 1/20,000 (men aged 18 to 30 years old). However, a conclusive causal link to vaccination has not been confirmed at this time. Additionally, two recently published European case reports describe myocarditis after COVID-19 mRNA vaccination in a 56-year-old man with previous COVID-19 and a 39-year-old man with no history of COVID-19. This report summarizes case histories of 7 healthy male adolescents 14 to 19 years of age who developed acute myocarditis or pericarditis within 4 days after receiving the second dose of the Pfizer-BioNTech COVID-19 vaccine, none of whom met criteria for MIS-C. All 7 patients were vaccinated in April and May of 2021 and have been reported to VAERS. Patient 6: A 16-year-old previously well male was admitted with a chief complaint of chest pain. His initial symptoms began 3 days after the second Pfizer-BioNTech COVID-19 vaccine with malaise and subjective fever. He had no recent or remote history of viral illness, and no known COVID-19 exposures. The night prior to admission he developed acute midsternal chest pain that lasted for approximately 18 hours. Evaluation in the ED showed an elevated troponin T (0.66 ng/mL, normal range, <0.01 ng/mL), ST-elevation on ECG but normal function and structure on echocardiogram. Cardiac MRI demonstrated diffuse edema and subepicardial late gadolinium enhancement. A nasopharyngeal SARS-CoV-2 PCR was negative and antibody testing showed positive spike and negative nucleocapsid antibodies for SARS-CoV-2. He was treated with 70 grams IVIG and started on prednisone 30 mg orally twice daily with a gradual taper over 4 weeks. He did not receive any non-steroidal anti-inflammatory drugs (NSAID). Troponin T climbed after admission and remained elevated throughout the hospitalization. Chest pain resolved after administration of 6 mg of morphine in the initial ED evaluation. Telemetry was normal throughout hospitalization. He was discharged 3 days after admission. He had not yet returned for follow-up visit at the time of this submission. Exposure to COVID-19 in 14 days prior to illness onset was None. The patient underwent lab tests and procedures which included activated partial thromboplastin time prolonged: 27.9 seconds, alanine aminotransferase: 22 (units/L), antibody test negative: negative, antibody test positive: antibody testing showed positive spike and negative nucleocapsid antibodies for SARS-CoV-2, aspartate aminotransferase: 59 (units/L), blood albumin: 3.8 g/dl, body mass index: 22, brain natriuretic peptide increased: 149 pg/ml, c-reactive protein: 1.5 mg/dl, c-reactive protein increased: 1.8 mg/dl, cytomegalovirus test negative: negative, echocardiogram: normal, electrocardiogram: st-elevated, ST-elevation on ECG but normal function, enterovirus test negative: negative, epstein-barr virus antibody negative: negative, International Normalized Ratio INR: 1.06, Other diagnostics: Negative Lyme serology, negative Mycoplasma serum PCR, negative Parvovirus serum PCR, Absolute lymphocyte count: 1.4/mm3, Absolute neutrophil: 2.8 /mm3, Platelet count: 189, Mycoplasma serum PCR: Negative, Respiratory pathogen panel PCR: Negative, Prothrombin time: 11.4 seconds, Erythrocyte sedimentation rate: 3 (mm/hr), COVID-19 spike antibody: Positive, Ferritin: 65 ug/L, Highest troponin: 0.82 ng/ml, Lowest troponin prior to Discharge: 0.01 ng/ml, Peripheral white blood cell count: 5.0. Discussion: Author report 7 cases of clinical myocarditis or myopericarditis that developed in 14 to 19-year-old males within 4 days of receiving the second dose of the Pfizer-BioNTech COVID-19 vaccine with no evidence of acute SARS-CoV-2 infection and who did not fulfill criteria for MIS-C. Extensive diagnostic evaluation for other myocarditis etiologies was negative, including respiratory pathogens from nasopharyngeal swabs, serum PCR tests, and infectious serologies. Additionally, all cardiac MRIs were diagnostic for myocarditis based on the modified Lake Louise criteria rather than MIS-C characteristics described by (withheld) et al (diffuse myocardial edema without evidence of late gadolinium enhancement). There was some suggestion of abnormal left ventricular myocardial echocardiographic strain corresponding to regions of myocardial necrosis on cardiac MRI. All patients in this series had myocarditis or myopericarditis, which is the term for diagnosis of both myocardial and pericardial inflammation. These terms are often used interchangeably, which can make surveillance of these diseases challenging. Myocarditis and pericarditis are rare diseases. The true baseline incidence of myocarditis is unknown and varies by season, geography, and age: it has been reported to occur in 1.95/100,000 person- years in children <15 years of age in Finland and in 2.16 cases per 100,000 US military service members in a 30-day period. It is more common in males, and among children demonstrates a bimodal incidence pattern, with peaks at <2 years of age and in adolescence. An evaluation for potential viral causes is recommended, although a cause is usually not found. There have been prior reports of myocarditis following smallpox vaccination10. In patients with myocarditis, restriction from competitive sports is recommended for at least 3 months until cleared by a cardiologist in order to avoid sudden cardiac events while the heart muscle recovers. Less is known about the true incidence of pericarditis. Pericarditis can occur in the setting of a variety of infectious and non-infectious illnesses. In a study of patients more than16 years of age in Finland, the incidence rate of hospitalizations for acute pericarditis was 3.32/100,000 person-years, with males at higher risk than females and in 2007, the incidence of acute pericarditis in one study was 27.2 cases per 100,000 per year. Treatment for myocarditis and pericarditis may vary considerably depending on the patient characteristics, clinical condition, underlying cause, and physician preference. Consistent with a known male preponderance of myocarditis and pericarditis, all seven of our cases were male. The Pfizer-BioNTech clinical trials demonstrated an increased systemic reactogenicity and immunogenicity in younger study participants following mRNA vaccine. For example, 41.5% of adolescents developed chills after dose #2, compared to 35.1% of subjects 18-55 years of age. In terms of immunogenicity, an analysis of SARS-CoV-2 50% neutralizing titers 1 month after dose#2 demonstrated higher geometric mean titer (GMT) in children 12-15 years of age (GMT=1,239.5), compared to subjects 16-25 years of age (GMT=705.1). Adverse events often occurred more frequently after dose #2 and within 2 days following vaccination and included injection site pain, fatigue, myalgia, chills, arthralgia, fever, injection site swelling or redness, nausea, malaise, and lymphadenopathy. It is possible that myocarditis or myopericarditis may be an additional rare adverse event related to systemic reactogenicity, but currently no causal association has been established between this vaccine and myopericarditis. In our case series, 6 patients received non-steroidal anti-inflammatory drug (NSAID) treatment. Four patients received IVIG and oral prednisone; one of these four patients also initially received high-dose methylprednisolone. The recognition of a possible temporal relationship of COVID-19 vaccine and myocarditis is critical, because the correct diagnosis may spare healthy adolescents and young adults presenting with chest pain and ECG ST elevation from undergoing unnecessary invasive medical procedures such as cardiac catheterization. It is unclear if treatment with intravenous immunoglobulin and/or corticosteroids, in the absence of MIS-C criteria, is warranted with all cases of myocarditis that develop temporally after COVID-19 vaccination. Notably, 3 patients recovered with NSAID therapy alone. Myocarditis and myopericarditis after COVID-19 vaccination appear rare. As of 23May2021, the Centers for Disease Control and Prevention (CDC) reports that 1,560,652 people <18 years of age have completed a two-dose series of COVID-19 vaccine17. Of these, 652, 758 adolescents received their second dose more than fourteen days ago17. Currently, the Pfizer-BioNTech COVID-19 vaccine is the only COVID-19 vaccine authorized for children <18 years of age in the US. We urge physicians and healthcare providers to consider myocarditis in the evaluation of adolescents and young adults who develop chest pain after COVID-19 vaccination. All cases of myocarditis in patients with recent COVID-19 vaccination should be reported promptly to VAERS. Our case series has inherent limitations. We compiled cases through personal communications between colleagues rather than using a systematic surveillance system to identify cases. It was not possible to exclude all alternative etiologies including idiopathic and other infectious etiologies, and there was not a systematic diagnostic evaluation for other viral etiologies. Cardiac biopsy was not performed on any patients, because they were all clinically stable during hospitalization. However, no patient had evidence of a preceding or concurrent symptomatic viral illness to implicate as an etiology of myocarditis, and the lack of eosinophilia dissuades a hypersensitivity reaction. The pathophysiology of myocarditis in these patients is indeterminate and we do not know if it is the same or different than classic myopericarditis or myopericarditis following other vaccines, associated with acute COVID-19, or MIS-C. Given the nature of a case series, we cannot determine the incidence rate of myocarditis/myopericarditis following COVID-19 mRNA vaccination. Finally, a negative nucleocapsid antibody does not conclusively rule out the possibility of natural infection. This report summarizes a series of US cases of myocarditis and myopericarditis following the Pfizer BioNTech COVID-19 mRNA vaccine in adolescent males. All cases in this report occurred after the second vaccine dose. Fortunately, none of our patients was critically ill and each was discharged home. At present, there is no definite causal relationship between these cases and vaccine administration. Information on the lot/batch number has been requested.; Sender''s Comments: Based on chronological connection to the vaccine causality between reported event acute myocarditis and Pfizer-BioNTech COVID-19 mRNA vaccine cannot be completely excluded. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees and Investigators, as appropriate.,Linked Report(s) : US-PFIZER INC-2021665013 Same reporter, drug, event but different patient

New Search

Link To This Search Result:

Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166